Alimta is an oncology drug owned by Lilly. The active ingredient in Alimta is pemetrexed disodium. This drug was first authorised for market use on 04 February, 2004.
Generic versions of Alimta are expected to be available after 24 May, 2022. This is the expiry date of the last patent for Alimta, US7772209*PED.
Alimta is used to treat certain types of cancer. Its active ingredient, pemetrexed disodium, works by slowing or stopping the growth of cancer cells.
Alimta holds one patent, US7772209*PED, which will expire on 2022-05-24. After this date, generic versions of Alimta can be produced. Below are the details of the patent: